The role of flow diversion for middle cerebral artery (MCA) aneurysms remains controversial due to frequent involvement of side branches and bifurcations. While outcomes have been reported in cohort studies and case series, the safety and efficacy of this approach remain uncertain. To evaluate angiographic and clinical outcomes following flow diversion for MCA aneurysms. A systematic literature search was performed across databases in accordance with PRISMA guidelines to identify studies reporting on flow-diverter treatment of MCA aneurysms. Studies including ≥3 patients treated with flow-diverter devices and reporting angiographic or clinical outcomes were eligible for inclusion. Thirty-three studies encompassing 1,036 MCA aneurysms met criteria, representing the largest cohort to date. Data on study design, patient and aneurysm characteristics, treatment details, and angiographic and clinical outcomes were extracted. Pooled estimates with 95% confidence intervals (CIs) were calculated using a random-effects model, with subgroup analyses by aneurysm location and device type. The pooled complete or near-complete occlusion rate was 71% at a mean follow-up of 15 months, with no significant differences across MCA segments (66% proximal, 69% bifurcation, 70% distal) or across device types. The overall complication rate was 13%, predominantly thromboembolic, with a 1% procedural mortality. Functional independence (mRS 0-2) was achieved in 90% of patients. Included studies were predominantly retrospective cohort series and case series with heterogeneity in device type, antiplatelet regimens, follow-up duration, and outcome definitions. Publication bias and underreporting of complications cannot be excluded. Flow diversion for MCA aneurysms achieves approximately 71% complete or near-complete occlusion with a 13% complication rate. These findings may support its consideration in carefully selected cases, though the retrospective evidence base warrants cautious interpretation.
BACKGROUND AND OBJECTIVES: Thorough and objective assessment is of utmost importance for any microsurgical laboratory training, allowing trainees to identify areas needing further improvement. The ideal assessment tool should be objective, reliable, self-administered, and easy to implement. Building on this necessity, the aim of this study was to establish an objective, reliable, and self-administered assessment tool for microsurgical laboratory training, enabling trainees to independently practice and assess their own results. METHODS: Eight trainees completed the Baskaya Microvascular Bypass Training Curriculum using a basic microsurgery training kit. Each trainee evaluated their 31 end products twice with the newly introduced Madison Objective Self-Assessment Tool (MOST). Subsequently, the same expert independently evaluated each trainee's end products once. These 3 sets of evaluations were compared using the intraclass correlation coefficient (ICC) to determine the reliability of the new self-assessment tool, both intrarater and interrater. RESULTS: The findings demonstrated that, aside from 2 exercises, the agreement levels for both interrater and intrarater ranged from excellent (ICC >0.90) to acceptable (ICC = 0.61-0.80). For the silicone tube (2 mm) end-to-end anastomosis with 9-0, the interrater ICC showed fair agreement, at 0.32 [−0.10 to 0.63], and for the chicken vessels side-to-side anastomosis with 10-0, interrater ICC demonstrated moderate agreement at 0.52 [0.16-0.76]. These results underscore the reliability of MOST. In addition, participant feedback highlighted its ease of use, requiring merely a few minutes to evaluate each end product. CONCLUSION: This study has demonstrated that the MOST is an effective, objective, and reliable tool for self-evaluation in microvascular anastomosis training, demonstrating high levels of agreement across most exercises and offering a user-friendly experience for trainees. This underscores its suitability as a valuable resource for enabling self-driven microvascular anastomosis training and assessment, especially in places where expert evaluation is unavailable.
Hypoxia–ischemia (HI)-related brain injury impacts millions of neonates worldwide. Male neonates are two times more susceptible to developing HI. We have previously reported that the administration of the neurotrophin receptor tyrosine kinase B (TrkB) agonist 7,8-dihydroxyflavone (DHF) following neonatal HI increases hippocampal TrkB phosphorylation and improves hippocampal-dependent learning and memory in early adult life only in females. We hypothesize that sex differences in HI outcomes are due to alterations in neonatal hippocampal steroid content, mainly the neural testosterone. At postnatal day 9, C57BL/6J mice underwent sham and Vannucci’s HI surgeries and were treated either with DHF or vehicle control. Hippocampi and plasma were collected on days 1 and 3 post-HI and liquid chromatography tandem mass spectrometry was used to determine the testosterone (T), estradiol (E2), progesterone (P4), and corticosterone (CORT) contents in these samples. All hippocampal steroid contents were at least 10-fold higher than in plasma, suggesting neural synthesis. Males had higher hippocampal T content than females at 3 days post-HI. Treatment with DHF reduced T in the female hippocampi at 3 days post-HI, but not in males. These findings suggest that the neuroprotective effect of DHF in females may be mediated, at least in part, through the reduction in hippocampal T following HI.